Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Price:
0.6671
USD
-0.54%
Market Closed
Market Cap:
$3.7m
Balance Sheet
Balance Sheet Decomposition
Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd
Balance Sheet Decomposition is not available for
Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd
Balance Sheet
Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd
Currency: USD
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
1
|
0
|
24
|
4
|
3
|
13
|
24
|
16
|
7
|
3
|
2
|
3
|
5
|
|
| Cash Equivalents |
0
|
1
|
0
|
24
|
4
|
3
|
13
|
24
|
16
|
7
|
3
|
2
|
3
|
5
|
|
| Short-Term Investments |
0
|
0
|
0
|
8
|
19
|
12
|
6
|
66
|
60
|
44
|
32
|
12
|
10
|
11
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
1
|
|
| Total Current Assets |
0
|
1
|
0
|
32
|
23
|
16
|
19
|
90
|
76
|
52
|
36
|
15
|
13
|
16
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
2
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
1
+407%
|
0
-78%
|
33
+19 271%
|
24
-26%
|
16
-32%
|
20
+19%
|
91
+361%
|
77
-15%
|
52
-32%
|
37
-30%
|
17
-55%
|
17
+0%
|
19
+11%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
1
|
1
|
2
|
3
|
2
|
2
|
6
|
7
|
5
|
3
|
2
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Liabilities |
1
|
1
|
2
|
1
|
3
|
5
|
4
|
3
|
7
|
8
|
6
|
3
|
3
|
2
|
|
| Long-Term Debt |
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
3
-4%
|
2
-23%
|
2
-28%
|
3
+79%
|
5
+98%
|
4
-28%
|
3
-30%
|
7
+169%
|
8
+13%
|
6
-26%
|
3
-49%
|
3
-12%
|
2
-21%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Retained Earnings |
7
|
10
|
28
|
37
|
47
|
64
|
77
|
86
|
107
|
136
|
168
|
186
|
193
|
200
|
|
| Additional Paid In Capital |
4
|
4
|
26
|
68
|
69
|
75
|
92
|
174
|
177
|
180
|
199
|
200
|
207
|
216
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Equity |
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
3
N/A
|
2
+27%
|
2
+2%
|
31
N/A
|
22
-31%
|
11
-49%
|
16
+43%
|
88
+456%
|
70
-21%
|
44
-37%
|
31
-31%
|
13
-56%
|
14
+3%
|
16
+18%
|
|
| Total Liabilities & Equity |
0
N/A
|
1
+407%
|
0
-78%
|
33
+19 271%
|
24
-26%
|
16
-32%
|
20
+19%
|
91
+361%
|
77
-15%
|
52
-32%
|
37
-30%
|
17
-55%
|
17
+0%
|
19
+11%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
0
|
2
|
|
Switch to:
Switch to:
See Also
Discover More
